Completed PHASE4 INTERVENTIONAL 1-arm NCT01301222

Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas (PD)

Randomized Controlled Trial on Role of Octreotide in Preventing Pancreatic Fistula and Complications After Pancreaticoduodenectomy in Patients With Soft Pancreas

Sponsor: PVS Memorial Hospital

Conditions Pancreatic Fistula

Interventions Inj. Octreotide

Updated 5 times since 2017 Last updated: Feb 21, 2015 Started: Sep 30, 2010 Primary completion: Sep 30, 2014 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01301222, this PHASE4 trial focuses on Pancreatic Fistula and remains completed. Sponsored by PVS Memorial Hospital, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PVS Memorial Hospital

Data source: PVS Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kochi, India